Join
Live feed
·
INSIDERFilingvia Quantisnow
Sonnet BioTherapeutics Holdings Inc. logo

Interim CEO Rao Raghu was granted 20,000 shares, increasing direct ownership by 849% to 22,356 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
SONN· Sonnet BioTherapeutics Holdings Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SONN (Sonnet BioTherapeutics Holdings Inc.) and more on Quantisnow.